the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Breast Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
CIRB18-1530 McCall, Anne Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
IRB17-0716 Hahn, Olwen A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer Details
IRB17-1219 Nanda, Rita An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments Details
CIRB17-0041 Nanda, Rita S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Details
CIRB16-1695 Hahn, Olwen A011502: A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer: The ABC Trail Details
CIRB16-0822 Hahn, Olwen Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Details
CIRB15-0239 Chmura, Steven NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Details
CIRB14-0810 Chmura, Steven NSABP-B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Details
IRB13-1365 Jaskowiak, Nora A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy Details
Phase II
Study No PI Title
IRB18-0663 Nanda, Rita A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes “Olaparib Expanded”
IRB18-0799 Nanda, Rita A Randomized, Phase II Study Comparing Trastuzumab And Vinorelbine In Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 AGONIST), In Patients With HER2-Positivie Metastatic Breast Cancer Who Have Progressed On Prior Trastuzumab And Pertuzumab (The AVIATOR Study)
IRB17-1611 Nanda, Rita A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease: Companion Immunologic and Genomic Correlative Studies Details
IRB17-1490 Nanda, Rita A Phase II, Open Label, Randomised, Multi- centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE) Details
CIRB17-1471 Nanda, Rita A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP inhibition (veliparib; ABT-888) and Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) Either alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) Details
IRB17-0602 Hahn, Olwen Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Details
IRB16-0403 Nanda, Rita A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Details
CIRB16-1399 Hahn, Olwen S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
CIRB15-0239 Chmura, Steven NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Details
IRB14-0424 Nanda, Rita A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer Details
10-183-B Nanda, Rita Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 Trial) Details
Phase I
Study No PI Title
IRB16-1383 Nanda, Rita A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1130 Chmura, Steven Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details
Study No PI Title
IRB16-1410 Abe, Hiroyuki MR Images to Predict Breast Lesions to be Benign or Malignant in Order to Reduce Unnecessary Biopsy
IRB17-0778 Nanda, Rita A pilot study to characterize the microbiome of triple-negative breast cancer patients
IRB16-0400 Giger, Maryellen Retrospective Database and Analysis of Breast Cancer Radiomics and Imaging Genomics
IRB16-0396 Schacht, David Development and Testing of an Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening = A Pilot Study
IRB14-0461 Karczmar, Gregory Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density
10-487-A O'Donnell, Peter The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing Details
15837A Chmura, Steven A Long Term Investigation of Curative Treatment in Breast Cancer Patients
9127 Karczmar, Gregory Improved MRi Images of Breast Lesions (not all cancer patients)

Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .